Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02874846 · ClinicalTrials.gov registry record · Phase 2
Nocturnal/Diurnal Intraocular Pressure-Lowering Effect of Netarsudil Ophthalmic Solution
A Phase 2 study, sponsored by Aerie Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT02874846 is a Phase 2 study that has completed, run by Aerie Pharmaceuticals. The registered enrollment target is 12 participants.
The verdict
NCT02874846, a Phase 2 study, has completed, sponsored by Aerie Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
To evaluate effect of Netarsudil Ophthalmic Solution 0.02% on Nocturnal and Diurnal Intraocular Pressure.
Interventions
- DRUG Netarsudil ophthalmic solution 0.02%
- OTHER Netarsudil Ophthalmic Solution Vehicle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2016-07 |
| Est. Completion | 2016-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02874846
The ClinicalTrials.gov registry entry for NCT02874846 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aerie Pharmaceuticals, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Netarsudil ophthalmic solution 0.02% is the first listed.
NCT02874846 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02874846 about?
NCT02874846 is a clinical study titled "Nocturnal/Diurnal Intraocular Pressure-Lowering Effect of Netarsudil Ophthalmic Solution". To evaluate effect of Netarsudil Ophthalmic Solution 0.02% on Nocturnal and Diurnal Intraocular Pressure.
What is the current status of trial NCT02874846?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2016-07. Estimated completion is 2016-09.
What interventions are being tested in trial NCT02874846?
The interventions under investigation include: Netarsudil ophthalmic solution 0.02% (DRUG), Netarsudil Ophthalmic Solution Vehicle (OTHER).
Who is sponsoring clinical trial NCT02874846?
This trial is sponsored by Aerie Pharmaceuticals, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.